Member Info for neilrich3

Https://x.com/DrEricDing/status/1808369949376733376

Https://www.linkedin.com/posts/primerdesign_primerdesign-launches-real-time-pcr-workflow-activity-7213477678090203137-qafL?utm_source=share&utm_medium=member_desktop

Would this new RUO test required a specific RNS, the reference within the Annual Report was sufficient. Also, would love to learn about the anticipated return, however I'd imagine that it shall be a low number, six figures at best.

It's a shame that other products don't get as much coverage, perhaps Yourgene should relaunch the DPYD test, having spent a considerable sum attaining IVDR certification, launched November 2023 it has all been very quiet since then.

Https://www.linkedin.com/feed/update/urn:li:activity:7212039441417187328?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A7212039441417187328%29

Hopefully they shall be pushing our saliva LFT, although presumably under the Yourgene Health, with it being clinical....but, who knows?! Not the shareholders that's for sure.

Https://www.linkedin.com/posts/primerdesign_oysters-norovirus-publichealth-activity-7212012585892622337-6xPo?utm_source=share&utm_medium=member_ios

Https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register

Https://www.linkedin.com/posts/primerdesign_oysters-norovirus-pathogendetection-activity-7211652403400470528-uPYZ?utm_source=share&utm_medium=member_desktop

Https://www.linkedin.com/posts/antonio-argenio-1aab7b22_pcr-partnership-scientificresearch-activity-7211355819093729280-R2BW?utm_source=share&utm_medium=member_desktop

Https://www.aquafeed.co.uk/primerdesign-launches-real-time-pcr-workflow-for-onsite-detection-of-norovirus-in-oysters/

Oyster & Clam Market size was valued at around USD 142 billion in 2022 and is estimated to reach USD 204.46 billion by 2032, owing to rising consumer demand for seafood and the popularity of raw bars and seafood restaurants.

They might be on to something.....clearly a growing market.

"So proud of the team at Primerdesign Ltd for developing this much needed solution, the UK Oyster market has been devoid of testing support for some time, and now with this innovative solution they can confidently test and supply product to both the domestic and international markets!"

Wonder what the potential market for testing is worth, domestic and international?

What's interesting here is the change in communication, utilising an external agency to improve the PR:

Codon develops curated PR solutions for transformational biotech companies at every stage to help establish brand credibility, raise awareness of their pioneering products, elevate their reputation as key opinion leaders, demonstrate corporate value to investors, and connect with customers and collaborators. Driven by PhD-level scientists with expertise in PR and marketing for bioscience companies, Codon offers a rare combination of high-level scientific understanding and more than a decade of experience in science communication. We pride ourselves on delivering scientifically sound content and a portfolio of reputation-building, audience-engaging PR for the life science industry through our trusted relationships with the trade media and global industry network.

Clearly Yourgene is selling products and services into the NHS, perhaps Lyn has a longer term game plan, for instance the DPYD Genotyping? What would you rather have, a cheque for £80m, or a contract award for £11m a year over five years. There may yet be method in the madness.

‘I have been disappointed with his tenure so far.‘

To be fair….Lyn has been at the helm for seven and a half weeks…there’s time yet!

Also, would appear that Novaprep is a registered trademark for Novacyt

Are we saying that potentially now £12.5m VAT to be returned as cash in the bank?

Https://kffhealthnews.org/news/article/bird-flu-tests-pandemic-possibility-preparedness/

Also included in trade and other receivables is a £8.5m VAT receivable balance (December 2022: £8.3m), that mainly relates to UK VAT paid on sales invoices in dispute with the DHSC. As these sales have not been recognised in accordance with IFRS 15, the revenue, trade receivable and VAT element of the transactions have been reversed, resulting in a VAT debtor balance.

Perhaps the above shall be used, in part, against the £24m upon the other side of the balance sheet. Then there's the £19.8m put aside to cover replacement of product under warranty.

Any thoughts upon what shall happen to the £24 million, from year end 2020, which is within trade receivables?